company background image
EVTA logo

Evotec DB:EVTA Stock Report

Last Price

€2.78

Market Cap

€993.8m

7D

-3.5%

1Y

-68.4%

Updated

10 Oct, 2024

Data

Company Financials +

EVTA Stock Overview

Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

EVTA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Evotec SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evotec
Historical stock prices
Current Share Price€2.78
52 Week High€11.00
52 Week Low€2.54
Beta1.05
11 Month Change-8.55%
3 Month Change-36.82%
1 Year Change-68.41%
33 Year Change-86.76%
5 Year Change-71.49%
Change since IPO181.52%

Recent News & Updates

Recent updates

Shareholder Returns

EVTADE Life SciencesDE Market
7D-3.5%-1.2%0.6%
1Y-68.4%-1.6%11.8%

Return vs Industry: EVTA underperformed the German Life Sciences industry which returned -1.3% over the past year.

Return vs Market: EVTA underperformed the German Market which returned 11.7% over the past year.

Price Volatility

Is EVTA's price volatile compared to industry and market?
EVTA volatility
EVTA Average Weekly Movement14.8%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: EVTA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: EVTA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
19935,022Christian Wojczewskiwww.evotec.com

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.

Evotec SE Fundamentals Summary

How do Evotec's earnings and revenue compare to its market cap?
EVTA fundamental statistics
Market cap€993.79m
Earnings (TTM)-€170.69m
Revenue (TTM)€788.44m

1.3x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVTA income statement (TTM)
Revenue€788.44m
Cost of Revenue€662.45m
Gross Profit€125.99m
Other Expenses€296.68m
Earnings-€170.69m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)-0.96
Gross Margin15.98%
Net Profit Margin-21.65%
Debt/Equity Ratio46.8%

How did EVTA perform over the long term?

See historical performance and comparison